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Abstract We have studied the effect of non-steroidal antiin-
flammatory drugs (NSAIDs) on KIIbL3 integrin activation and
platelet aggregation. NSAIDs such as meloxicam, piroxicam,
indomethacin and aspirin, but not aceclofenac or diclofenac
interfered with the activation state of KIIbL3. NSAIDs that
inhibited KIIbL3 activation were also able both to partially
inhibit platelet primary aggregation and to accelerate platelet
deaggregation. These effects of NSAIDs were not dependent on
cyclooxygenase inhibition. The results obtained indicate that
some NSAIDs exert a specific action on KIIbL3 activation, and
provide an additional mechanism that accounts for their
beneficial effects in diseases in which platelet activation is
involved.
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1. Introduction
Platelet activation can be initiated by several mechanical
(vessel wall injury, disruption of atherosclerotic plaques) or
chemical (ADP, epinephrine, thromboxane A2, thrombin)
stimuli. In response to vessel wall injury, platelets attach to
subendothelial matrix (adhesion) that is followed by ¢brino-
gen-mediated platelet-platelet interaction (aggregation). Si-
multaneously, platelets release their intracellular granule con-
tents (secretion) that lead to the recruitment of additional
circulating platelets (ampli¢cation). Platelet aggregation is
mediated exclusively by KIIbL3, an integrin that binds ¢bri-
nogen, ¢bronectin, von Willebrand factor and vitronectin
[1,2].
As other integrins, KIIbL3 can be found in di¡erent a⁄nity
states for their ligands. Variations in the ligand-binding a⁄n-
ity of integrins (integrin activation) occur within seconds after
cell stimulation as a consequence of intracellular signals [3,4]
and are due to changes in the conformation of the extracel-
lular domain of these molecules [5]. In this regard, several
antibodies have been described that speci¢cally recognize neo-
epitopes that are expressed only by activated integrins [6^8].
Upon platelet activation, KIIbL3 undergoes a measurable con-
formational change in its quaternary structure [9,10], switch-
ing from low to a high-a⁄nity state. These structural changes
allow the binding of soluble ¢brinogen ending in thrombi
formation.
Non-steroidal antiin£ammatory drugs (NSAIDs) are a het-
erogeneous group of chemical compounds very commonly
prescribed for disorders characterized by in£ammation or
thrombosis. Although the inhibition of prostaglandin synthe-
sis has been proposed to be the mechanism of action of
NSAIDs, there are evidences that suggest that additional
functions may be implicated. In this regard, we have recently
described that some NSAIDs such as indomethacin, diclofe-
nac, aspirin, ketoprofen and aceclofenac induce L-selectin
shedding from neutrophil cell membrane, thereby preventing
the adhesion of neutrophils to endothelial cells [11]. On the
other hand, NSAIDs from the oxicam family are able to in-
terfere with neutrophil L-selectin shedding and KML2 integrin
up-regulation induced by pro-in£ammatory cytokines [12]. In
addition, these drugs inhibit the appearance of activation-de-
pendent epitopes on L2 and L1 integrins in cytokine-stimu-
lated neutrophils and T lymphocytes, respectively [12].
Although it is accepted that some NSAIDs interfere with
the platelet secondary aggregation through the inhibition of
platelet degranulation, recently described e¡ects of these
agents on integrin activation prompted us to examine whether
NSAIDs could inhibit the platelet aggregation through the
modulation of KIIbL3 activation. In the present work, we
report that some NSAIDs are able both to inhibit the primary
aggregation of platelets induced by agonists through the in-
hibition of KIIbL3 integrin activation as well as to increase the
rate of deaggregation independently of cyclooxygenase inhib-
ition.
2. Materials and methods
2.1. Antibodies and reagents
Prostaglandin I2 (PGI2), ADP, epinephrine, piroxicam, diclofenac,
aspirin (acetylsalicylic acid) and indomethacin were purchased from
Sigma Chemical Co (St. Louis, MO, USA). Aceclofenac was obtained
from Prodesfarma (Barcelona, Spain) and meloxicam from
Boeºhringer Ingelheim GmbH (Ingelheim, Germany). All NSAIDs
were solubilized in dimethyl sulfoxide (DMSO) (Panreac, Barcelona,
Spain) and were incubated with platelets in a ¢nal concentration of
0.2% DMSO. All control data were obtained in the presence of 0.2%
DMSO. Thrombin was from Boeºhringer Mannheim GmbH (Ger-
many). Acid solubilized type I collagen was from ICN Biomedicals
(Costa Mesa, CA, USA). Fluorescein isothiocyanate (FITC)-conju-
gated goat anti-mouse Igs was purchased from Dako (Salstrup, Den-
mark). Thromboxane B2 (TXB2) Immunoassay was from R and D
Systems (United Kingdom). Ro43-5054 is an KIIbL3-speci¢c non-pep-
tide antagonist that has been described previously [13]. The non-in-
hibitory anti-KIIbL3 mAb D57 [14] was kindly provided by Dr. M.H.
Ginsberg, anti-KIIbL3 activated mAb PAC-1 [7] was a generous gift
from Dr. S. Shattil and anti-P-selectin mAb S12 [15] was kindly do-
nated by Dr. R.P. McEver. P3X63 myeloma culture supernatant was
used as negative control.
FEBS 21704 15-3-99
0014-5793/99/$20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 0 2 3 6 - 7
*Corresponding author. Fax: +34 (1) 520 23 74.
E-mail: fsmadrid/princesa@hup.es
Abbreviations: DMSO, dimethyl sulfoxide; mAb, monoclonal anti-
body; NSAIDs, non-steroidal antiinflammatory drugs; PGI2, pros-
taglandin I2 ; PRP, platelet rich plasma; TXB2, thromboxane B2
FEBS 21704FEBS Letters 446 (1999) 318^322
2.2. Platelet isolation
Platelet isolation was carried out at room temperature from normal
human venous blood mixed with bu¡ered sodium citrate 0.13 M in
the proportion 10:1. Platelet rich plasma (PRP) was obtained by
centrifugation of whole blood at 1100 rpm for 10 min. To isolate
washed platelets, 1 WM PGI2 was added to PRP, and platelets were
collected by centrifugation at 2200 rpm for 10 min. The pellet was
gently resuspended in PBS pH 7.3, supplemented with 0.1% BSA,
1 WM PGI2, and centrifuged at 2200 rpm for 10 min. Finally, washed
platelets were gently resuspended in PBS, 0.1% BSA, 0.1 mM CaCl2,
1 mM MgCl2. To isolate gel-¢ltered platelets, PRP was passed over a
column of Sepharose 2B (Pharmacia Fine Chemicals).
2.3. Flow cytometry analysis
Binding of mAbs to resting or agonist activated platelets was ana-
lyzed by £ow cytometry, using P3X63 myeloma culture supernatant as
negative control. Washed platelets were incubated in some assays with
NSAIDs for 20 min at 37‡C. Di¡erent stimuli (ADP, epinephrine,
thrombin, collagen) were added immediately. After an incubation of
5 min at 37‡C, aliquots of untreated or NSAIDs pre-treated platelets
were incubated with saturating concentrations of speci¢c mAbs at
room temperature. After 15 min incubation, cells were labeled with
FITC-conjugated goat anti-mouse Igs (1:50 ¢nal dilution) for an ad-
ditional 15 min at room temperature. Platelets were ¢nally ¢xed with
an equal volume of 4% formaldehyde for 2 h at 4‡C, washed, and
resuspended in PBS.
Flow cytometry analysis was performed with a FACScan cyto£uo-
rometer (Becton Dickinson, Mountain View, CA, USA). Linear and
logarithmic £uorescence values from at least 1U104 platelets per sam-
ple were obtained in each experiment. In experiments where the £uo-
rescence was recorded in linear scale, the £uorescence gain was ad-
justed so that 5% of cells of the sample with greatest £uorescence were
positive in the highest £uorescence channel. The results are presented
in some ¢gures as the mean £uorescence intensity (MFI). In order to
minimize the variations between di¡erent blood donors, in experi-
ments with NSAIDs, data were normalized to express relative per-
centage of variation of MFI (r %vMFI) of PAC-1 binding. First, we
calculate the percentage of variation of MFI (%vMFI) in each sample
respect to basal MFI of resting platelets as follows:
%vMFISAMPLE  MFISAMPLE=MFIBASAL31U100:
Then, r %vMFI of stimulated samples previously incubated with
NSAIDs respect to vehicle treated samples was calculated as follows:
r %vMFI  %vMFINSAIDAGONIST=%vMFIDMSOAGONISTU100;
where r %vMFI of vehicle treated (control) platelets was 100%.
2.4. Platelet dense granules secretion
Platelet secretion of dense granules ATP was monitored with a
manual luminometer (Lumat LB9501, Berthold), using the ATP Bio-
luminescence Assay Kit HSII (Boeºhringer Mannheim GmbH, Ger-
many). Platelet ATP secretion of untreated and activated platelets
was expressed as relative light units.
2.5. Platelet aggregation
Platelet aggregation studies were performed with PRP using a four-
channel aggregometer (Menarini, Firenze, Italy). Autologous platelet
poor plasma was prepared by centrifugating blood at 3500 rpm for 10
min at room temperature. Platelet concentration in PRP was adjusted
to 3U105 platelets/Wl by adding platelet poor plasma. To study the
e¡ect of NSAIDs on platelet primary aggregation, PRP was preincu-
bated with these substances added in a ¢nal concentration of 0.2%
DMSO for 15 min at 37‡C. Then, aggregation was induced by adding
1 WM ADP to the aggregometer cuvette and stirring at 1100 rpm.
Aggregation was monitored for 5 min and is expressed as percentage
of change in light transmittance. The rate of deaggregation is arbitra-
rily expressed as percentage of change in light transmittance/min cal-
culated during the 45 s following the maximal aggregation.
2.6. Platelet thromboxane B2 production
Thromboxane generation was determined in gel-¢ltered platelets.
Gel-¢ltered platelets were incubated with NSAIDs solubilized in
0.2% DMSO for 10 min at 37‡C, and then activated with 1 mM
arachidonic acid for 5 min at 37‡C. Reaction was quenched by addi-
tion of ice-cold ethanol, samples were centrifuged at 14 000 rpm for
5 min at room temperature, ethanol was evaporated and the pellet
resuspended in immunoassay bu¡er. Determination of the stable end-
product of TXA2, TXB2, was analyzed using a TXB2 Immunoassay
according to the manufacturer’s protocol (R and D Systems).
2.7. Statistical analysis
Results were expressed as arithmetic mean þ standard error of the
mean (S.E.M.) or standard deviation (S.D.). Student’s t-test for paired
samples was used to determine signi¢cant di¡erences between means.
3. Results
To determine KIIbL3 activation state, we analyzed the ex-
pression of a speci¢c activation-dependent epitope on this in-
tegrin by the PAC-1 mAb. This mAb recognizes the ligand-
binding site of the activated form of KIIbL3 [16], and the
expression of the epitope recognized by PAC-1 indicates the
ability of this integrin to bind soluble ¢brinogen. Platelets
were activated with low doses of di¡erent agonists (epineph-
rine, ADP and type I collagen), to avoid the release of endog-
enous agonist stored into platelet granules. The expression
levels of KIIbL3 activation-dependent epitope and P-selectin,
and the ATP release from dense granules under these activa-
tion conditions are shown in Fig. 1 (A, C and D, respectively).
We found that 1 WM epinephrine, 1 WM ADP or 50 Wg/ml
collagen activated KIIbL3 integrin but were unable to induce
P-selectin expression and dense granules secretion, while 0.02
U/ml thrombin induced a signi¢cant granules release reaction
as con¢rmed by increase in the binding of anti-P-selectin mAb
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Fig. 1. Expression of activated KIIbL3 integrin, P-selectin, and ATP
release in platelets activated with low doses of agonists. Platelets
were activated with either 1 WM epinephrine, 1 WM ADP, 50 Wg/ml
collagen or 0.02 U/ml thrombin. Platelets were then stained with
PAC-1 mAb (A), D57 mAb (B) or S12 mAb (C) and bound £uores-
cence was analyzed by £ow cytometry. Data are expressed as the
arithmetic mean þ S.E.M. of the MFI from eight independent ex-
periments. D: ATP release for untreated and agonist-treated plate-
lets was analyzed in a luminometer. Results are expressed as the
arithmetic mean þ S.E.M. of the relative light units from four inde-
pendent experiments.
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and ATP detection. The incubation of platelets with epineph-
rine, ADP or collagen at those doses did not modify the basal
expression of KIIbL3 as indicated by D57 mAb binding (Fig.
1B). However, the basal expression of KIIbL3 integrin on
platelet surface was slightly increased during incubation with
thrombin (Fig. 1B), likely as a consequence of KIIbL3 trans-
location from K and dense granules [17,18]. This point was
con¢rmed by analysis of surface expression of P-selectin (Fig.
1C), which is also a component of both sorts of granules in
platelets [15,18]. In this study we have used these mild activa-
tion conditions to analyze the e¡ect of NSAIDs on KIIbL3
integrin activation in the absence of platelet granule release.
To determine whether NSAIDs interfere with KIIbL3 integ-
rin activation in platelets, we examined the e¡ect of di¡erent
NSAIDs on the conformational changes of KIIbL3 induced by
di¡erent stimuli. Pretreatment of platelets with meloxicam,
piroxicam, aspirin and indomethacin inhibited the expression
of the activation-dependent epitope on KIIbL3 induced by 1
WM epinephrine (Fig. 2A). A partial inhibitory e¡ect of PAC-
1 epitope expression was also observed when the agonist used
was 1 WM ADP (Fig. 2B). The inhibitory e¡ect of NSAIDs on
KIIbL3 integrin activation induced by either epinephrine or
ADP was dose dependent, with a more noticeable inhibition
on the activation induced by epinephrine (Fig. 3). The inhib-
itory e¡ect of meloxicam was stronger than that of piroxicam
upon L3 integrin activation. In contrast, aceclofenac and di-
clofenac were unable to prevent KIIbL3 activation induced by
both epinephrine and ADP (Fig. 3). Collagen-induced KIIbL3
activation was also inhibited by meloxicam, piroxicam and
aspirin but not by indomethacin (Fig. 2C). Finally, the acti-
vation of KIIbL3 induced by the potent agonist thrombin was
only partially inhibited by aspirin and indomethacin whereas
no e¡ect was found with oxicams (Fig. 2D). Moreover, indo-
methacin and aspirin caused a signi¢cant inhibition on P-se-
lectin surface expression after thrombin activation (data not
shown), thus indicating an inhibitory e¡ect of these NSAIDs
on granule secretion, as previously described [19,20]. In con-
trast, meloxicam and piroxicam did not show any signi¢cant
e¡ect on P-selectin expression (data not shown).
To study the e¡ect of NSAIDs on platelet primary aggre-
gation, assays were carried out in the presence of low doses of
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Fig. 2. E¡ect of NSAIDs on KIIbL3 activation-dependent epitope
expression induced by di¡erent agonists. Platelets were pretreated
with meloxicam (20 Wg/ml or 57 WM), piroxicam (40 Wg/ml or 120
WM), aspirin (250 Wg/ml or 1.4 mM), indomethacin (40 Wg/ml or
112 WM) or DMSO prior to agonists addition. A: 1 WM epineph-
rine. B: 1 WM ADP. C: 50 Wg/ml collagen. D: 0.02 U/ml thrombin.
The data are expressed as the aritmethic mean þ S.E.M. of four in-
dependent experiments.
Table 1
E¡ect of NSAIDs on platelet primary aggregation
Aggregation (% change
in light transmittance)
Control 37.8 þ 0.7
Meloxicam 20 Wg/ml 25.0 þ 1.2*
Piroxicam 20 Wg/ml 27.0 þ 1.6*
Indomethacin 20 Wg/ml 28.3 þ 1.2*
Aspirin 250 Wg/ml 28.2 þ 1.3*
Aceclofenac 20 Wg/ml 36.5 þ 2.4
Ro 43-5054 2 WM 0
Data are expressed as the aritmethic mean þ S.E.M. obtained in six
independent assays.
*P6 0.01 (Student’s t-test for paired samples).
Fig. 3. Dose-response of the e¡ect of NSAIDs on PAC-1 binding to
activated platelets. Platelets were preincubated with di¡erent concen-
trations of NSAIDs. Then, platelets were activated with 1 WM epi-
nephrine (b), 1 WM ADP (F) for 5 min at 37‡C. PAC-1 binding
was measured by £ow cytometry, and data are expressed as the arit-
methic mean þ S.E.M. from four experiments.
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ADP (1 WM). The term primary aggregation refers to the
direct aggregation of platelets incubated with a low concen-
tration of agonist that does not induce granule secretion [21].
We found that the treatment of platelets with meloxicam,
piroxicam, indomethacin or aspirin partially prevented pri-
mary aggregation (Table 1). In contrast, aceclofenac did not
a¡ect platelet maximal primary aggregation. Furthermore,
meloxicam, piroxicam, indomethacin and aspirin also signi¢-
cantly increased the initial rate of platelet deaggregation
(P9 0.01) (Fig. 4A and B). Platelet aggregation was solely
mediated by the interaction of KIIbL3 with ¢brinogen, since
the Ro43-5054 compound, that prevents the binding of ¢bri-
nogen to KIIbL3, completely abolished the platelet aggrega-
tion in these assays (Table 1).
To ascertain whether the e¡ect of NSAIDs on KIIbL3 acti-
vation was dependent or not on the inhibition of cyclooxy-
genase, we analyzed the e¡ect of NSAIDs on the production
of TXB2. The basal TXB2 production was 3459 þ 802 pg/108
platelets and it was increased to 84 709 þ 5529 pg/108 platelets
after activation with 1 mM arachidonic acid. Treatment of
platelets with indomethacin and aspirin inhibited dramatically
TXB2 generation after arachidonic acid stimulation (Fig. 5),
whereas the treatment with meloxicam did not exert any sig-
ni¢cant inhibitory e¡ect on TXB2 formation (Fig. 5). Togeth-
er these results indicate that the inhibitory e¡ects of di¡erent
NSAIDs on platelet KIIbL3 integrin activation and aggrega-
tion take place regardless of their e¡ects on cyclooxygenase
inhibition.
4. Discussion
Most NSAIDs are able to inhibit cyclooxygenase, interfer-
ing with the metabolism of arachidonic acid and therefore
with thromboxane A2 formation in platelets. However, these
drugs have many biochemical e¡ects that do not involve pros-
taglandin synthesis which indicate that the e¡ects of NSAIDs
seem to be drug- and cell-type dependent [22^24]. In this re-
port we provide an additional mechanism that may account
for NSAIDs bene¢cial e¡ect in diseases in which platelet ag-
gregation is involved. Hence, we found that some NSAIDs are
able to inhibit platelet aggregation through the inhibition of
KIIbL3 integrin activation in a cyclooxygenase-independent
manner.
Signals elicited by weak agonists (ADP, epinephrine, colla-
gen) do not induce granules release reaction by themselves
and cause a partial reversible platelet aggregation. Strong ag-
onists (thrombin) activate phospholipase C, increasing cyto-
plasmic free calcium and activating protein kinase C, and
these events synergistically stimulate granules secretion and
cause a complete non-reversible platelet aggregation [25].
The low doses of agonists employed in this report allowed
us to study the regulation of KIIbL3 integrin activation in
the absence of a complete platelet activation, as determined
by the failure to increase P-selectin expression and ATP re-
lease, indicating that this integrin activation is a very early
and rapid event during platelet activation. The signalling
mechanisms involved in the conformational changes that ac-
tivate KIIbL3 integrin are not completely understood, but in-
volve at least seven transmembrane protein receptors, G pro-
teins, phospholipases, calcium release, arachidonic acid
metabolism, protein kinase C, adenyl and guanyl cyclases,
and other protein kinases and phosphatases [26]. Our data
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Fig. 4. E¡ect of NSAIDs on the rate of platelet deaggregation. PRP
was incubated with meloxicam (20 Wg/ml), piroxicam (20 Wg/ml), in-
domethacin (20 Wg/ml) or aspirin (250 Wg/ml). A: Representative ag-
gregometer tracing. B: Rate of deaggregation. Data are expressed
as the arithmetic mean þ S.E.M. obtained in ten independent assays.
*P6 0.01 (Student’s t-test for paired samples).
Fig. 5. Thromboxane B2 production is inhibited by some NSAIDs.
Gel-¢ltered platelets were preincubated with di¡erent NSAIDs (250
Wg/ml aspirin; 20 Wg/ml indomethacin and meloxicam). TXB2 pro-
duction is expressed as arithmetic mean þ S.D. of three independent
experiments. *P6 0.01 (Student’s t-test for paired samples).
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indicate that oxicams only prevent integrin activation induced
by weak agonists. These drugs induced their highest inhibition
of KIIbL3 activation when platelets were stimulated with col-
lagen. Under this condition, indomethacin did not exert any
e¡ect suggesting that KIIbL3 activation induced by collagen
might be independent of arachidonic acid metabolism. Integ-
rin activation mediated by ADP and epinephrine was partially
inhibited by all NSAIDs except aceclofenac and diclofenac,
probably because several intracellular pathways are elicited by
these stimuli.
Interestingly, the interference of NSAIDs with integrin
KIIbL3 activation has functional consequences on platelet pri-
mary aggregation. This platelet initial aggregation is inde-
pendent of agonists endogenous release and TXA2 produc-
tion. The e¡ect of NSAIDs on platelet primary aggregation
seems to be a consequence of both a partial inhibition of
maximal KIIbL3 activation and an increase in the rate of
deactivation of this integrin. Hence, platelet aggregation,
mediated by KIIbL3 interaction with ¢brinogen, seems to be
more stable in untreated platelets than in NSAID-treated
platelets. These results suggest that these drugs could directly
a¡ect regulation of KIIbL3 activation either by interfering
with intracellular signalling events that change integrin con-
formation through their cytoplasmic tail or by modifying in-
tegrin-cytoskeleton interactions.
Indomethacin and aspirin inhibited events mediated by
both weak (integrin activation) and strong agonists (integrin
activation and granule secretion). These data are in agreement
with the work of Shattil and Brass [27], that describes that
indomethacin inhibits the expression of the PAC-1 neoepitope
in platelets treated with low doses of thrombin. In this regard,
it has been described that aspirin and indomethacin decrease
the ¢brinogen binding to platelets induced by epinephrine,
apparently by prevention of both dense granules and TXA2
release, which may potentiate the platelet response [19,20].
Our results con¢rm that aspirin and indomethacin strongly
inhibit TXA2 formation, indicating that these drugs inhibit
cyclooxygenase-1, the enzyme isoform present in platelets.
Nevertheless, the inhibitory e¡ect on cyclooxygenase is not
common to all NSAIDs, as we show that meloxicam did
not signi¢cantly inhibit cyclooxygenase at the doses used in
this study. Therefore, our data support the issue that the
e¡ects of NSAIDs on KIIbL3 activation do not correlate to
their capability to inhibit cyclooxygenase, and indicate that
each NSAID may have more than one mechanism of action.
Thus, we conclude that some NSAIDs can interfere with one
of the ¢rst events of platelet activation: ¢brinogen receptor
activation, an e¡ect that diminishes platelet aggregation trig-
gered by low doses of agonist. The molecular mechanisms
responsible of the action of NSAIDs on KIIbL3 activation
remain to be elucidated. This novel e¡ect of NSAIDs could
play an important role during pathological processes where
traces of platelet agonists could lead to microthrombi forma-
tion.
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